Jafron Biomedical Co

Jafron Biomedical Co Rule of 40

The Rule of 40 of Jafron Biomedical Co (300529.SZ) as of Nov 13, 2026 is 11.90 %. In the previous year, Rule of 40 was 78.32 % — a change of -84.80% (lower).

Rule of 40

11.90 %

YoY

-84.80%

Last updated:

Rule of 40 of Jafron Biomedical Co is 2025 11.90 % . Rule of 40 of Jafron Biomedical Co was 2024 78.32 % . It decreases by -84.80% lower compared to the previous year.

The Jafron Biomedical Co Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
88.34 CNY
Jan 1, 2019
88.37 CNY
Jan 1, 2020
90.29 CNY
Jan 1, 2021
90.15 CNY
Jan 1, 2022
34.44 CNY
Jan 1, 2023
5.45 CNY
Jan 1, 2024
78.32 CNY
Jan 1, 2025
11.90 CNY
The Jafron Biomedical Co Rule of 40 history
YEARRule of 40YoY
11.90 %-84.80%
78.32 %+1,337.71%
5.45 %-84.18%
34.44 %-61.79%
90.15 %-0.16%
90.29 %+2.17%
88.37 %+0.04%
88.34 %+12.77%
78.33 %+57.85%
49.62 %-40.06%
82.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Rule of 40 of Jafron Biomedical Co is 11.90 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Quality — Jafron Biomedical Co

AAQSPiotroski F-ScoreAltman Z-ScoreGraham NumberRule of 40

All Key Metrics — Jafron Biomedical Co